Table 1 Clinical characteristics of rectal cancer patients
From: Role of tumor cell senescence in non-professional phagocytosis and cell-in-cell structure formation
Pre RCT biopsies | Post RCT tumor resections | ||
|---|---|---|---|
n (%) | n (%) | ||
Variable | All patients | 96 (100) | 146 (100) |
Gender | male | 63 (65.6) | 110 (75.3) |
female | 33 (34.4) | 36 (24.7) | |
Age at diagnosis | mean | 64 y (35–93 y) | 63 y (33–84 y) |
UICC stage | I | 7 (7.3) | 8 (5.5) |
II | 24 (25) | 34 (23.3) | |
III | 52 (54.2) | 81 (55.5) | |
IV | 13 (13.5) | 23 (15.8) | |
Grading | G1 | 4 (4.2) | 3 (2.1) |
G2 | 77 (80.2) | 116 (79.5) | |
G3 | 15 (15.6) | 27 (18.5) | |
T stage | T1 | 4 (4,2) | 3 (2.1) |
T2 | 13 (13.5) | 18 (12.3) | |
T3 | 72 (75) | 105 (71.9) | |
T4 | 7 (7.6) | 20 (13.7) | |
N stage | N0 | 32 (33.3) | 48 (32.9) |
N1 | 64 (66.7) | 98 (67.1) | |
N2 | 0 (0) | 0 (0) | |
N3 | 0 (0) | 0 (0) | |
M stage | M0 | 83 (86.5) | 123 (84.2) |
M1 | 13 (13.5) | 23 (15.8) | |
Chemotherapy | 5-FU mono | 38 (39.6) | 53 (36.3) |
Oxaliplatin - 5-FU | 42 (43.8) | 76 (52.1) | |
other 5-FU-combinations | 7 (7.3) | 5 (3.4) | |
others | 9 (9.4) | 12 (8.2) | |
Dworak regression grade | 0 | 1 (1) | 3 (2.1) |
1 | 8 (8.3) | 9 (6.2) | |
2 | 22 (22.9) | 55 (37.7) | |
3 | 53 (55.2) | 79 (54.1) | |
4 | 12 (12.5) | 0 (0) |